Screener
Jade Biosciences JBIO Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Jade Biosciences in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Jade Biosciences’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:27 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212088
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Total assets | $319,433 | $349,781 |
| Liabilities, Convertible Preferred Stock and Stockholders' Equity (Deficit) | ||
| Current liabilities: | ||
| Accounts payable | 3,979 | 2,151 |
| Accrued expenses and other current liabilities | 14,852 | 9,419 |
| Related party accrued expenses and other current liabilities | 794 | 4,969 |
| Warrant liability, related party | 2,667 | — |
| Total current liabilities | 22,292 | 16,539 |
Item 1. Financial Statements.
FAQ
- What is Jade Biosciences's accounts payable?
- Jade Biosciences (JBIO) reported accounts payable of $3.98M in Q1 2026.
- How has Jade Biosciences's accounts payable changed year-over-year?
- Jade Biosciences's accounts payable increased by 5666.7% year-over-year, from $69K to $3.98M.
- What is the long-term trend for Jade Biosciences's accounts payable?
- Over 5 years (2020 to 2025), Jade Biosciences's accounts payable has grown at a 28.3% compound annual growth rate (CAGR), from $618K to $2.15M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Jade Biosciences's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude